4basebio Share Discussion Threads

[buzzzzzzzz] 12/4/2024 13:41

RNS re Tier 1 Pharma

Good news just keeps coming.

[pob69] 21/3/2024 08:29

Here's the CEO of Helixnano on the trials;

[buzzzzzzzz] 10/3/2024 22:30

Dont I know it!!!

[chicken charlie] 09/3/2024 09:23

chicken charlie is

[buzzzzzzzz] 08/3/2024 16:58

You are right great RNS.

Are you a holder I do not check in that often as I do not think anyone else is in this?

[babbler] 01/3/2024 07:28

Looks like you will be fine. Nice rns this morning.

[buzzzzzzzz] 29/2/2024 17:09

An all time high.........Huzzah!

[buzzzzzzzz] 10/2/2024 10:22

A profit is a profit, well done!

I am in for the long haul!

Wish me luck!

[hydrus] 07/2/2024 08:03

BUzzzz - sorry for delay no I am not. Watching with interest but I exited with a good profit after a portfolio review.

[buzzzzzzzz] 02/2/2024 16:00

Todays RNS is a clear signal the company is for sale.

Question is at what price and what timeframe , CEO and CFO have a great incentive looking at the bonus stated in the RNS.

Interesting times!

[buzzzzzzzz] 13/2/2023 12:17

Zours increasing his holding through Delphi.........must be confident!

[gsbmba99] 08/2/2023 07:56

A bit of coverage for the sector.

[buzzzzzzzz] 30/9/2022 08:40

pob69

Thanks for posting!

[pob69] 30/9/2022 07:40

Finncap comment;

...results reflect consistent progress towards its main objective of producing GMP-grade synthetic DNA, while at the same time it is building incremental value into the business through product/technology expansion with first commercial sales of its DNA and increasing corporate partnerships. It generated revenues of £0.15m with adjusted pre-tax loss of £2.7m (H1 2021: £1.8m, +45%) and ended the period with £5.6m cash. Despite the expected increase in cashburn as headcount increases, near-term funding is not considered an issue, given that it can draw down from its €25m loan facility.

...minor changes to forecasts to reflect increased headcount and higher capex, with year-end cash forecast to be £1.9m (previously £2.3m). We maintain our sum-of-the-parts DCF target price of 1,200p, which is underpinned by the expected high demand for DNA/RNA and the significant potential of its technology to address key challenges in the cell and gene therapy space.

[hydrus] 09/8/2022 08:47

Good to hear Buzz. Looking forward to how this interesting company progresses over next few years.

[buzzzzzzzz] 09/8/2022 07:36

Well done Hydrus.

I went to the AGM steady progress being made.

[hydrus] 03/8/2022 12:38

Great recovery here - still holding

[buzzzzzzzz] 01/8/2022 21:31

free stock charts from uk.advfn.com

[buzzzzzzzz] 01/8/2022 21:30

Nice rise, downtrend broken!

[buzzzzzzzz] 25/7/2022 16:34

Nice to see the CFO pick up another 5,000 shares in June.

Management certainly putting their money where their mouth is!

Decent buying today pushing price back up.

[buzzzzzzzz] 23/5/2022 17:16

RNS 11th and 12th May.

Looks like they were able to buy after the results.

I will probably go to the AGM.

[buffetteer] 23/5/2022 16:07

Where did you see that Pls …can’t find it

[buzzzzzzzz] 23/5/2022 15:38

Good to see the CEO and CFO dipping into their pockets to the tune of 16,600 and 19,300 respectively!!

A real vote of confidence.

[buzzzzzzzz] 15/2/2022 11:02

Great runs today
Production will start on schedule and with first commercial order.
A real coup nicking cooper from ABCAM he must have faith in 4BB.

[buzzzzzzzz] 05/1/2022 08:26

I see the CEO continues to add to his substantial position.

Big vote of confidence in the business!!